Phase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients
Safety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with 3 different types of cancers in 3 parts of the study, as shown below:
Part 1 - Neoadjuvant Therapy of Breast Cancer;
Part 2 - Therapy of Ovarian Cancer; and
Part 3 - Therapy of Gastric Cancer.
100 项与 Excellabio LLC 相关的临床结果
0 项与 Excellabio LLC 相关的专利（医药）
100 项与 Excellabio LLC 相关的药物交易
100 项与 Excellabio LLC 相关的转化医学
